<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565188</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 01-092.3</org_study_id>
    <secondary_id>ZonMW 1135.0010</secondary_id>
    <nct_id>NCT00565188</nct_id>
  </id_info>
  <brief_title>Application of ATP Infusions in Palliative Home Care</brief_title>
  <official_title>Application of Adenosine 5'-Triphosphate (ATP) Infusions in Palliative Home Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Palliative care in cancer aims at alleviating the suffering of patients. A previous study in
      patients with advanced non-small-cell lung cancer showed that adenosine 5'-triphosphate (ATP)
      infusions had a favourable effect on fatigue, appetite, body weight, muscle strength,
      functional status, quality of life, and survival. Based on these promising results, the
      present study was designed 1. To evaluate whether the beneficial effects of ATP
      administration observed in patients with advanced lung cancer would also be present in
      pre-terminal cancer patients of different tumour types, and 2. To test the feasibility of
      application of ATP infusions in a home care setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival Physical restriction Fatigue Quality of life</measure>
    <time_frame>0-8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appetite Nutritional intake Body height Body weight Triceps skin fold thickness Mid-upper arm circumference Strength of elbow flexor and knee extensor muscles Handgrip strength Process evaluation</measure>
    <time_frame>0-8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cancer</condition>
  <condition>Palliative Care</condition>
  <condition>Survival</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine 5'-triphosphate</intervention_name>
    <description>Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cytologically or histologically confirmed cancer

          -  medical treatment options restricted to supportive care

          -  a life expectancy &lt; 6 months

          -  World Health Organization (WHO) performance status 1 or 2

          -  suffering from at least one of the following complaints: fatigue, weight loss &gt; 5%
             over the last 6 months, or anorexia

        Exclusion Criteria:

          -  symptomatic angina pectoris

          -  symptomatic heart failure

          -  any form of atrioventricular (AV) block (assessed by electrocardiogram)

          -  life expectancy &lt; 4 weeks

          -  concurrent palliative chemotherapy

          -  cognitive dysfunction, and other diseases hampering adequate follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P.C. Dagnelie, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University - Department of Epidemiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maxima Medical Center</name>
      <address>
        <city>Eindhoven</city>
        <zip>5600 PD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium MC</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Hospital</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000 Feb 16;92(4):321-8.</citation>
    <PMID>10675381</PMID>
  </reference>
  <reference>
    <citation>Agteresch HJ, Rietveld T, Kerkhofs LG, van den Berg JW, Wilson JH, Dagnelie PC. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol. 2002 Jan 15;20(2):371-8.</citation>
    <PMID>11786563</PMID>
  </reference>
  <reference>
    <citation>Agteresch HJ, Burgers SA, van der Gaast A, Wilson JH, Dagnelie PC. Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs. 2003 Sep;14(8):639-44.</citation>
    <PMID>14501386</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2007</study_first_submitted>
  <study_first_submitted_qc>November 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2007</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

